Follow-up standard agglutination and 2-mercaptoethanol tests in 175 clinically cured cases of human brucellosis

International Journal of Infectious Diseases

Volumn 14, Issue 3, 2010, Pages

  Roushan, Mohammad Reza Hasanjani ^a   Amiri, Mohammad Jafar Soleimani ^a   Laly, Abolghasem ^a   Mostafazadeh, Amrollah ^a   Bijani, A ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

2 Mercaptoethanol (2 ME); Brucellosis; Follow up; Standard agglutination test (SAT); Treatment

Indexed keywords

DOXYCYCLINE; GENTAMICIN; MERCAPTOETHANOL; STREPTOMYCIN;

ADULT; AGGLUTINATION TEST; ARTICLE; BRUCELLOSIS; CLINICAL EVALUATION; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROBABILITY; RELAPSE; SEROLOGY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGGLUTINATION TESTS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BRUCELLA; BRUCELLOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MERCAPTOETHANOL; MIDDLE AGED; TIME FACTORS;

EID: 77949315120     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.05.008     Document Type: Article

References (22)

1. Young E.J. An overview of human brucellosis. Clin Infect Dis 21 (1995) 283-290
2. Hasanjani Roushan M.R., Mohrez M., Smailnejad Gangi S.M., Soleimani Amiri M.J., and Hajiahmahmadi M. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect 132 (2004) 1109-1114
3. th ed. (1995), Churchill Livingstone, New York 2053-2060
4. Solera J., Martinez-Alfaro E., and Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 53 (1997) 245-256
5. Araj G.F., Lulu A.R., and Mustafa M.Y. Evaluation of ELISA in the diagnosis of acute and chronic brucellosis. Hygiene (London) 97 (1986) 457-469
6. Sirmatel F., Turker M., and Bozkurt A.I. Evaluation of the methods used for the serologic diagnosis of brucellosis. Mikrobiyol Bul 36 (2002) 161-167
7. Buchanan T.M., and Faber L.C. 2-Mercaptoethanol agglutination test: usefulness for predicting recovery from brucellosis. Clin Microbiol 11 (1980) 691-693
8. Acocella G., Bertrand A., Baytout J., Durrande J.B., Garcia- Rodriquez J.A., Kosmidis J., et al. Comparison of three different regimens in the treatment of acute brucellosis: a multinational study. J Antimicrob Agents Chemother 23 (1989) 433-439
9. Solera J., Rodriguez- Zapata M., Geijo P., Largo J., Paulino J., Saez L., et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 39 (1995) 2061-2067
10. Ariza J., Gudiol F., Pallares R., Viladrich P.F., Rufi G., Corredoira J., et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. Ann Intern Med 117 (1992) 25-30
11. Solera J., Martinez-Alfaro E., and Espinoza A. Recognition and optimum treatment of brucellosis. Drugs 53 (1997) 245-256
12. Montejo J.M., Albert I., Zarate P.G., Alvarez A., Alonso J., Canovas A., et al. Open randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 16 (1993) 671-676
13. Corbel M.J., and Beeching N.J. Brucellosis. In: Kasper D.L., Fauci A.S., Longo D.L., Braunwald E., Hauser S.L., and Jameson J.L. (Eds). Harrison's principles of internal medicine. 16th ed. (2005), McGraw-Hill, New york 914-917
14. Araj G.F. Human brucellosis-revisited: persistent saga in the Middle East. BMJ Middle East 7 (2000) 6-15
15. Ariza J., Corredoira J., Pallares R., Viladrich P.F., Rufi G., Pujol M., et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 20 (1995) 1241-1249
16. Gazapo E., Lahoz J.G., and Subiza J.L. Changes in IgM and IgG antibody concentration in brucellosis over time. Importance for diagnosis and follow-up. J Infect Dis (1989) 219-225
17. Ariza J., Pellicer T., Foz A., and Gudiol F. Specific antibody profile in human brucellosis. Clin Infect Dis 14 (1992) 131-140
18. Almuneef M., and Memish Z.A. Prevalence of Brucella antibodies after acute brucellosis. J Chemother 15 (2003) 148-151
19. Mantur B.G., Biradar M.S., Bidri R.C., Mulimani M.S., Veerappa K., Kariholu P., et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years experience in an endemic area. J Med Microbiol 55 (2006) 897-903
20. Kiel F.W., and Khan M.Y. Analysis of 506 consecutive positive serologic tests for brucellosis in Saudi Arabia. Clin Microbiol 25 (1987) 1384-1387
21. Navarro E., Segura J.C., Castano M.J., and Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin Infect Dis 42 (2006) 1266-1273
22. Maas K.S., Mendez M., Zavaleta M., Manrique J., Franco M.P., Mulder M., et al. Evaluation of brucellosis by PCR and persistence after treatment in patients returning to the hospital for follow-up. Am J Trop Med Hyg 76 (2007) 698-702